** Shares of Moderna MRNA.O fall 3.28% to $32.48 premarket
** U.S. health officials are reevaluating a $590 million contract that was awarded to co for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources
** The review is part of a government push to examine spending on messenger RNA-based vaccines, the technology that powered Moderna's COVID vaccine, the report added
** The U.S. government awarded MRNA $590 million in January to advance the development of its bird flu vaccine
** Shares have fallen nearly 65% in the last 12 months
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。